Sign in
Not yet taking people in NetherlandsPhase 3

Tests hospital-made CAR T-cells against standard care for returned multiple myeloma

Compares hospital-made CAR T-cells with standard treatment in adults with relapsed myeloma.

Key facts

Who runs it
Universitair Medisch Centrum Groningen
Where
Groningen, NetherlandsSee the site
Registry title
A study investigating the safety and efficacy of academically-produced CAR T cells compared with standard treatment for patients with multiple myeloma whose disease has returned or not responded to previous treatments.
Status
Not yet recruiting
Phase
Phase 3
People taking part
126 people, planned
Started
1 Aug 2026
Expected to end
1 Aug 2030
Type of study
Interventional
Record updated
29 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with multiple myeloma that came back or stopped responding after 2 to 4 earlier treatments. It compares ARI0002h CAR T-cells with standard treatment.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Multiple myeloma that no longer responds to the last treatment, with disease that can be measured at screening. ECOG/WHO performance status of 0-2.
Earlier treatment
Must have had 2 to 4 earlier lines of myeloma treatment, including an IMiD, a PI and an anti-CD38 antibody. Must not have had BCMA-targeted therapy, T-cell engager therapy, CAR T-cell therapy or other genetically modified T-cell therapy.

Main reasons for not taking part

  • Myeloma in the brain, spinal fluid or heart
  • Plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome or amyloidosis
  • Uncontrolled infection or infection needing IV antimicrobials
  • Pregnant or breastfeeding women, or people not willing to use highly effective birth control
  • Life expectancy under 12 weeks, or taking part in another clinical trial

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Documented historical diagnosis of Multiple Myeloma
  • Received 2 to 4 prior lines of antimyeloma therapy, including an IMiD, a PI and an anti-CD38 mAb
  • Refractory to the last line of treatment by IMWG criteria
  • Measurable disease at screening per IMWG criteria
  • Candidates to receive at least 1 of the 5 SoC regimens (PVd, PCd, EPd, DKd or Kd)
  • Aged 18 years or older
  • Capable of giving informed consent
  • ECOG/WHO performance status of 0-2
  • Adequate hematological, renal, hepatic, pulmonary, and cardiac function

Who cannot take part

  • Received one of the following prior therapies: BCMA-targeted therapy, T-cell engager therapy, CAR T-cell therapy, or other genetically modified T-cell therapy
  • Active or prior history of central nervous system (CNS) or meningeal involvement of MM
  • Cardiac atrial or cardiac ventricular MM involvement
  • History of or active plasma cell leukemia, Waldenstrom’s macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes (POEMS) syndrome, or amyloidosis
  • Presence or suspicion of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management
  • Females who are pregnant or breastfeeding
  • Participants who are not willing to practice highly effective birth control
  • Life expectancy < 12 weeks
  • Current participation in another clinical trial

Where in Netherlands

  • Universitair Medisch Centrum GroningenGroningen, NetherlandsNot yet recruiting

About the trial

What the trial wants to find out

To compare progression free survival (PFS) of patients randomized to PoC ARI0002h CAR T-cells versus current SoC in patients previously treated with 2-4 lines of therapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
HO183 CAR T: A phase III randomized trial comparing academically produced BCMA-directed CAR T-cells (ARI0002h) with standard of care regimen in patients with relapsed/refractory multiple myeloma
Plain-language title
Tests hospital-made CAR T-cells against standard care for returned multiple myelomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
29 April 2026